CIK 0001601830
- Large accelerated filer
RECURSION PHARMACEUTICALS, INC.
Sign in to watch- Ticker
- RXRX
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 464099738
- Phone
- +1 385-269-0203
- Business address
- 41S RIO GRANDE STREET, SALT LAKE CITY, UT, 84101
- Former names
- Recursion Pharmaceuticals, LLC
- 4 Grant or award Director acquired 1,647 shares (grant or award)
- 4 Grant or award Director acquired 1,734 shares (grant or award)
- 4 Grant or award Chief Financial Officer acquired 370,343 shares (grant or award)
- 4 Shares withheld for taxes Chief Financial Officer gave up 22,725 shares (to pay taxes)
- 4 Planned sale Chief Executive Officer sold 40,000 shares at an average $7.14 ($285,600)
- 3 Insider Initial Statement of Ownership
- 4 Grant or award Director acquired 105,037 shares (grant or award)
- 3 Insider Initial Statement of Ownership
- 4 Shares withheld for taxes Chief Medical Officer gave up 4,187 shares (to pay taxes)
- 4 Shares withheld for taxes Chief Financial Officer gave up 11,937 shares (to pay taxes)
- 4 Shares withheld for taxes President and COO gave up 14,286 shares (to pay taxes)
- 4 Shares withheld for taxes Chief Executive Officer gave up 26,023 shares (to pay taxes)
- 4 Planned sale Chief Executive Officer sold 40,000 shares at an average $7.55 ($301,800)
- 4 Planned sale Director sold 11,447 shares at $7.64 ($87,457)
- 4 Planned sale Chief Financial Officer sold 30,000 shares at an average $7.65 ($229,505)
- 4 Planned sale Director sold 11,447 shares at $6.72 ($76,926)
- 4 Planned sale President and COO sold 6,000 shares at $6.31 ($37,855)
- 4 Planned sale Director sold 11,447 shares at $6.67 ($76,326)
- 4 Planned sale Chief Financial Officer sold 30,000 shares at an average $6.34 ($190,131)
- 4 Grant or award Director acquired 2,026 shares (grant or award)
Page 7 of 26 · 512 filings